Exelon Corp.'s Form 3 lists VP & Corporate Controller Caroline Fulginiti as directly holding 2,439 common shares in an entry dated October 5, 2026.
Exelon Corp director Matthew C. Rogers acquired 897 deferred phantom share equivalents on September 30, 2026. His reported balance after the transaction was 2,436 equivalents, including 15 accrued through automatic dividend reinvestment. The equivalents are held in his Exelon stock fund account within a multi-fund, non-qualified deferred compensation plan and are settled for cash on a 1-for-1 basis upon termination of his board service.
Exelon Corp director Charisse R. Lillie acquired 6 deferred phantom share equivalents on September 30, 2026. Her reported balance was 3,941 equivalents, including 39 additional equivalents accrued through automatic dividend reinvestment. The equivalents are held in her Exelon stock fund account within a multi-fund, non-qualified deferred compensation plan and will be settled for cash on a 1-for-1 basis when her board service ends.
Exelon Corp. (EXC) director Marjorie Rodgers Cheshire acquired 511 deferred phantom share equivalents as an award on September 30, 2026. Her reported balance afterward was 11,162 phantom share equivalents, including 105 additional equivalents accrued through automatic dividend reinvestment. The equivalents are held in her Exelon stock fund account within a multi-fund, non-qualified deferred compensation plan and will be settled for cash on a 1-for-1 basis upon termination of her service to the board of directors.
Exelon Corp. director William P. Bowers acquired 1,067 deferred phantom share equivalents on September 30, 2026, as an award. His reported balance after the transaction was 22,546 equivalents, including 212 additional equivalents accrued through automatic dividend reinvestment. The equivalents are held in his Exelon stock fund account as part of a multi-fund, non-qualified deferred compensation plan.
Exelon Corp. (EXC) announced significant leadership changes and compensation terms for several executives. Michael Innocenzo will depart his roles as Exelon’s Executive Vice President and Chief Operating Officer, President and CEO of PECO, and Board Chair of Commonwealth Edison Company in 2027 on a date to be determined, remaining in place to support an orderly transition.
Effective October 5, 2026, Jeanne Jones will become Executive Vice President of Finance and Strategy, adding corporate strategy to her existing finance responsibilities. On the same date, Robert Kleczynski will become Executive Vice President and Chief Financial Officer and Exelon’s principal financial officer, and Caroline Fulginiti will become Vice President and Controller and Exelon’s principal accounting officer. Effective January 1, 2027, Josh Levin will become Senior Vice President of Finance at Exelon and Andrew Plenge will become Chief Financial Officer of ComEd. Exelon set new pay packages for Kleczynski, Fulginiti and Plenge, including base salaries and long-term incentive awards, and reaffirmed 2026 Adjusted (non-GAAP) operating earnings guidance of $2.81–$2.91 per share and expected cumulative annualized Adjusted operating earnings growth from 2025–2029 near the top of the 5%–7% range.
Exelon Corporation ownership disclosure: BlackRock, Inc. reports beneficial ownership of 103,668,925 shares of Exelon common stock, representing 10.1% as set forth in this amendment dated 06/30/2026. The filing lists 95,799,095 shares as sole voting power and 103,668,925 as sole dispositive power.
Exelon Corp director Matthew C. Rogers received a grant of deferred phantom share equivalents as part of his compensation. On the transaction date, he acquired 778 deferred phantom share equivalents tied to Exelon common stock at a reference price of $46.62 per share. These units are held in his Exelon stock fund account within a multi-fund, non-qualified deferred compensation plan and will be settled in cash on a 1-for-1 basis when his board service ends. After this grant and dividend-related accruals, his balance in this plan totals 1,524 phantom share equivalents, including 7 units added through automatic dividend reinvestment.
Lillie Charisse R reported acquisition or exercise transactions in this Form 4 filing.
Exelon Corp director Charisse R. Lillie received a grant of 5 deferred phantom share equivalents tied to Exelon common stock. These were awarded at a reference price of $46.62 per equivalent and increase her deferred phantom share balance to 3,896 equivalents.
The phantom share equivalents are held in an Exelon stock fund account within a multi-fund, non-qualified deferred compensation plan and will be settled in cash on a 1-for-1 basis after her service on the board ends. The balance includes 35 additional equivalents that accrued automatically through dividend reinvestment, highlighting this as compensation and deferral activity rather than open-market trading.
Cheshire Marjorie Rodgers reported acquisition or exercise transactions in this Form 4 filing.
Exelon Corp director Marjorie Rodgers received a compensation grant of 442 deferred phantom share equivalents of Exelon common stock at a reference price of $46.62 per equivalent. This increased her balance in the Exelon stock fund account under a multi-fund, non-qualified deferred compensation plan to 10,547 phantom share equivalents.
These phantom share equivalents will be settled for cash on a 1-for-1 basis when her service on the board of directors ends. The balance includes 91 additional phantom share equivalents that accrued automatically through dividend reinvestment in the plan.